These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38702396)

  • 1. The evolving treatment landscape of metastatic urothelial cancer.
    Roviello G; Santoni M; Sonpavde GP; Catalano M
    Nat Rev Urol; 2024 Oct; 21(10):580-592. PubMed ID: 38702396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
    Casuscelli J; von Amsberg G; Retz M
    Urologie; 2024 Oct; 63(10):1002-1010. PubMed ID: 39235511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.
    Gong J; Reimers MA
    Adv Ther; 2024 Sep; 41(9):3441-3451. PubMed ID: 39023740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
    Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
    Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
    Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
    Int J Clin Oncol; 2024 Aug; 29(8):1096-1104. PubMed ID: 38850448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab
    Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Nakamura M; Harada K; Fujimoto N
    Anticancer Res; 2024 Aug; 44(8):3419-3426. PubMed ID: 39060065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
    Rodriguez-Vida A; Valderrama BP; Castellano D; Pinto A; Mellado B; Puente J; Climent MA; Domenech M; Vazquez F; Perez-Gracia JL; Bonfill T; Morales-Barrera R; Gonzalez-Billalabeitia E; Garcia-Del-Muro X; Maroto P; Navarro-Gorro N; Juanpere N; Juan O; Bellmunt J
    ESMO Open; 2024 Sep; 9(9):103690. PubMed ID: 39214051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.
    Di Civita MA; Torchia A; Santini D; Marinelli D; Magro V; Cerro M; Pappalardo L; Maltese G; Santamaria F; Zacco L; Buccilli D; Dehghanpour A; Speranza I; Sciarra A; Panebianco V; Roberto M
    Curr Oncol; 2024 Aug; 31(8):4713-4727. PubMed ID: 39195335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
    Miyake M; Nishimura N; Oda Y; Miyamoto T; Iida K; Inoue K; Tachibana A; Yoshikawa T; Sakamoto K; Ohnishi M; Maesaka F; Takamatsu N; Mieda K; Ohmori C; Matsubara T; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
    Int J Clin Oncol; 2024 Sep; 29(9):1311-1325. PubMed ID: 38888683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    Hepp Z; Shah SN; Smoyer K; Vadagam P
    J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.
    Tonni E; Oltrecolli M; Pirola M; Tchawa C; Roccabruna S; D'Agostino E; Matranga R; Piombino C; Pipitone S; Baldessari C; Bacchelli F; Dominici M; Sabbatini R; Vitale MG
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
    Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA
    Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis.
    Hinojosa-Gonzalez DE; Saffati G; Salgado-Garza G; Patel S; Kronstedt S; Jones JA; Taylor JM; Yen AE; Slawin JR
    Urol Oncol; 2024 Nov; 42(11):361-369. PubMed ID: 39112104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.